MiR-203 Expression Predicts Outcome After Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Liver
Overview
Authors
Affiliations
Many recent studies have shown the utility of microRNAs (miRs) as cancer-related biomarkers. The aim of the present study was to evaluate the correlation between miR-203 expression and prognosis of patients with hepatocellular carcinoma (HCC) and cirrhosis after liver transplantation (LT). Sixty-six HCC samples from patients who had undergone LT were examined for miR-203 expression using quantitative reverse transcription-polymerase chain reaction. The data were correlated with clinicopathological parameters and prognosis. Patient survival was analyzed by the Kaplan-Meier method and log-rank test. Cox regression was used for multivariate analysis of prognostic factors. We found that miR-203 expression was low in tumor tissues of patients (n = 16) with post-LT HCC recurrence in comparison with those in patients with non-recurrence (n = 50) (P = 0.003). Patients with higher miR-203 expression had significantly better recurrence-free survival (RFS) and overall survival (OS) (P = 0.016 for RFS; P = 0.014 for OS). Multivariate analysis revealed that high-miR-203 expression was an independent predictor of good prognosis (HR 0.202, P = 0.006 for RFS; HR 0.332, P = 0.013 for OS). Our results suggest that miR-203 could be a novel prognostic marker in HCC patients who have undergone LT and might also be a potential therapeutic target.
Jeng L, Chan W, Teng C Discov Oncol. 2025; 16(1):281.
PMID: 40056315 PMC: 11890906. DOI: 10.1007/s12672-025-02043-y.
Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Badwei N J Clin Exp Hepatol. 2023; 13(5):804-812.
PMID: 37693263 PMC: 10482986. DOI: 10.1016/j.jceh.2023.02.006.
Abdo S, Shousha W, Mohamed A, Elshobaky M, Saleh M, Ali M J Genet Eng Biotechnol. 2023; 21(1):85.
PMID: 37587273 PMC: 10432369. DOI: 10.1186/s43141-023-00537-2.
microRNA-203 functions as a natural Ras inhibitor in hepatocellular carcinoma.
Guo J, Li L, Deng N, Xu Y, Wang G, Luo H Am J Cancer Res. 2023; 13(4):1295-1309.
PMID: 37168327 PMC: 10164818.
Bhat M, Clotet-Freixas S, Baciu C, Pasini E, Hammad A, Ivanics T Clin Proteomics. 2021; 18(1):27.
PMID: 34794390 PMC: 8600773. DOI: 10.1186/s12014-021-09333-x.